Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial-Reference-Cited by-同舟云学术

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

Published:2018-02 Issue:10122 Volume:391 Page:748-757
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Powles Thomas,Durán Ignacio,van der Heijden Michiel S,Loriot Yohann,Vogelzang Nicholas J,De Giorgi Ugo,Oudard Stéphane,Retz Margitta M,Castellano Daniel,Bamias Aristotelis,Fléchon Aude,Gravis Gwenaëlle,Hussain Syed,Takano Toshimi,Leng Ning,Kadel Edward E,Banchereau Romain,Hegde Priti S,Mariathasan Sanjeev,Cui Na,Shen Xiaodong,Derleth Christina L,Green Marjorie C,Ravaud Alain

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study;Loehrer;J Clin Oncol,1992

2. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer;von der Maase;J Clin Oncol,2005

3. Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up;Bellmunt;Ann Oncol,2014

4. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract;Bellmunt;J Clin Oncol,2009

5. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer;Choueiri;J Clin Oncol,2012

Cited by 1154 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic effect of cancer therapy;Metabolomics of Bladder Cancer;2025

2. Developing and experimental validating a B cell exhaustion-related gene signature to assess prognosis and immunotherapeutic response in bladder cancer;Gene;2024-11

3. Letter Re: High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma;European Journal of Cancer;2024-10

4. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study;Clinical Genitourinary Cancer;2024-10

5. An Overview of Immune Checkpoint Inhibitor Toxicities in Bladder Cancer;Toxicology Reports;2024-09